Medical Affairs PharmD Fellow

Company Overview

Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc., is a biopharmaceutical company focused on developing innovative solutions for patients and healthcare providers in the fields of Critical Care and Infectious Diseases.

Our mission to deliver innovative, life‑saving medicines for serious unmet medical conditions drives us every day and contributes to building a sustainable business for the long term. It also inspires our entrepreneurial culture which fosters innovation, collaboration, and a relentless commitment to the people we serve. Patients are at the center of everything we do because everyday matters. Every employee is encouraged to take initiative, explore new ideas, and turn challenges into opportunities that can potentially transform lives, especially those suffering from serious and difficult‑to‑treat illnesses.

• GIAPREZA® (angiotensin II) is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock.
• XACDURO® (sulbactam for injection; durlobactam for injection) is a new treatment designed specifically to treat hospital‑acquired bacterial pneumonia (HABP) and ventilator‑associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii‑calcoaceticus complex in adults.
• XERAVA® (eravacycline) is a broad‑spectrum antibiotic used to treat patients with complicated intra‑abdominal infections (cIAI).
• ZEVTERA® (ceftobiprole) is an approved advanced‑generation cephalosporin antibiotic and the only FDA‑approved cephalosporin specifically designed to treat adult patients with Staphylococcus aureus bloodstream infections (bacteremia) including those with right‑sided infective endocarditis. In addition, Zevtera is approved in adult patients with acute bacterial skin and skin structure infections (ABSSSI), and adult and pediatric patients (3 months to less than 18 years old) with community‑acquired bacterial pneumonia (CABP).
• NUZOLVENCE® (zoliflodacin) for oral suspension is a first‑in‑class, single‑dose oral antibiotic for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents 12 years of age and older weighing at least 35 kg.

The Medical Affairs Fellow will serve as an integral member of the Innoviva Specialty Therapeutics (IST) Medical Affairs team, contributing to strategic and scientific initiatives that support IST’s portfolio of critical care and infectious disease therapies.

As the inaugural fellow, this individual will gain broad exposure across medical strategy and operations, scientific communications, medical information, evidence generation, and cross‑functional collaboration. The fellow will work closely with Medical Affairs leadership to support disease awareness, interpret emerging clinical data, develop scientific resources, and ensure responsible communication of scientific insights. Through partnership with the Industry Pharmacists Organization (IPhO), the fellow will additionally participate in national professional development, leadership activities, and networking within a broader community of industry fellows.

• Contribute to and help execute Medical Affairs strategic and tactical plans.
• Assist with disease awareness, therapeutic education, and evidence‑generation initiatives.
• Support preparation of advisory board materials and capture key insights to inform strategy.

• Interpret and summarize clinical trial data to support scientific messaging and Medical Affairs strategy.
• Assist with development and review of scientific slide decks, FAQs, medical response letters, and educational resources.
• Support the creation and review of abstracts, posters, and manuscripts for scientific meetings.

• Support the development of scientifically accurate, fair‑balanced medical information resources.
• Contribute to the creation of field‑facing scientific tools and training materials for the MSL team.

• Participate in optional rotations with Field Medical Affairs and other functional areas (Regulatory, Clinical…